Samarium-153 therapy for prostate cancer: The evaluation of urine activity, staff exposure and dose rate from patients


PARLAK Y., Gumuser G., Sayit E.

Radiation Protection Dosimetry, vol.163, no.4, pp.468-472, 2015 (SCI-Expanded, Scopus) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 163 Issue: 4
  • Publication Date: 2015
  • Doi Number: 10.1093/rpd/ncu237
  • Journal Name: Radiation Protection Dosimetry
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.468-472
  • Manisa Celal Bayar University Affiliated: Yes

Abstract

The aim of this study was to determine the excretion of Samarium-153-ethylenediaminetetramethylphosphonic acid (153Sm- EDTMP) in urine and to calculate the dose rate of its retention in the body as a function of time and the dose received by the skin of laboratory staff 's finger. Urine samples were collected from 11 patients after intravenous injection of 153Sm-EDTMP. The measurements of dose rate were performed. Thermoluminescent dosemeters were used for absorbed dose measurements. Effective half-lives that were calculated from urine sample measurements were found as 7.1±3 h within the first 24 h. Whole body dose rates before collecting urine of patients were 60.0 ± 15.7 μSv h21 for within 1 h following 153Sm-EDTMP administration. The highest finger radiation dose is to the right-hand thumb (3.8 ± 2 mGy). The results of the study imply that patients who recieved 153Sm-EDTMP therapy should be kept a minumum of 8 h in an isolated room at hospital and that one staff should give therapy at most two patients per week.